Interestingly, the preliminary results of a Phase IIb clinical trial (NCT03233230) on another BTK inhibitor evobrutinib (also known as M2951 or MSC2364447C) demonstrate that it is effective in RA patients with an inadequate response to methotrexate (www.clinicaltrials.gov). Here, BTK is linked to rheumatoid arthritis.